Demographics and clinical presentation
| . | Standard-risk patients (n = 114) . | |
|---|---|---|
| . | N . | % . |
| Age, y from study entry, median, range | 1.68 | 0.66-3.55 |
| Sex | ||
| Male | 54 | 47.4 |
| Female | 60 | 52.6 |
| Race | ||
| American Indian or Alaska Native | 2 | 2.0 |
| Asian | 5 | 5.1 |
| Black or African American | 16 | 16.3 |
| White | 72 | 73.5 |
| Multiple races | 3 | 3.1 |
| Unknown | 16 | |
| Ethnicity | ||
| Hispanic | 30 | 27.8 |
| Not Hispanic | 78 | 72.2 |
| Unknown | 6 | |
| History of TAM | ||
| No | 81 | 71.1 |
| Yes | 33 | 28.9 |
| Prior treatment of TAM | ||
| No | 23 | 69.7 |
| Yes | 10 | 30.3 |
| CNS status41 | ||
| 1 | 90 | 88.2 |
| 2a | 5 | 4.9 |
| 2b | 4 | 3.9 |
| 2c | 1 | 1.0 |
| 3a | 1 | 1.0 |
| 3c | 1 | 1.0 |
| Unknown | 12 | |
| Patient diagnosed with non-CNS extramedullary disease at study entry | ||
| No | 112 | 98.2 |
| Yes: orbit site | 2 | 1.8 |
| . | Standard-risk patients (n = 114) . | |
|---|---|---|
| . | N . | % . |
| Age, y from study entry, median, range | 1.68 | 0.66-3.55 |
| Sex | ||
| Male | 54 | 47.4 |
| Female | 60 | 52.6 |
| Race | ||
| American Indian or Alaska Native | 2 | 2.0 |
| Asian | 5 | 5.1 |
| Black or African American | 16 | 16.3 |
| White | 72 | 73.5 |
| Multiple races | 3 | 3.1 |
| Unknown | 16 | |
| Ethnicity | ||
| Hispanic | 30 | 27.8 |
| Not Hispanic | 78 | 72.2 |
| Unknown | 6 | |
| History of TAM | ||
| No | 81 | 71.1 |
| Yes | 33 | 28.9 |
| Prior treatment of TAM | ||
| No | 23 | 69.7 |
| Yes | 10 | 30.3 |
| CNS status41 | ||
| 1 | 90 | 88.2 |
| 2a | 5 | 4.9 |
| 2b | 4 | 3.9 |
| 2c | 1 | 1.0 |
| 3a | 1 | 1.0 |
| 3c | 1 | 1.0 |
| Unknown | 12 | |
| Patient diagnosed with non-CNS extramedullary disease at study entry | ||
| No | 112 | 98.2 |
| Yes: orbit site | 2 | 1.8 |
CNS 1, absence of blasts on cytospin preparation of CSF; CNS 2a, <5/μL WBCs and cytospin positive for blasts in CSF containing <10/μL RBCs; CNS 2b, <5/μL WBCs and cytospin positive for blasts in CSF containing ≥10/μL RBCs; CNS 2c, ≥10/μL RBCs, ≥5/μL WBCs and cytospin positive in CSF containing a ratio of WBC to RBC that is not greater than twice that found in the peripheral blood; CNS 3a, ≥5/μL WBCs and cytospin positive for blasts in CSF containing <10/μL RBCs; CNS 3b, ≥5/μL WBCs and ≥10/μL RBC in CSF containing a ratio of WBC to RBC that is greater than twice that found in peripheral blood; CNS 3c, clinical signs of CNS leukemia (eg, cranial nerve palsy, involvement of brain/eye) cerebrospinal fluid; RBC, red blood cell; WBC, white blood cell.